[Hepatoprotective and immunomodulating effect of phylloquinone in toxic damage to the liver].
On entering the organism D-galactosamine (DGA) induces the development of biochemical syndromes of hepatocyte affection, increases the intensity of lipid peroxidation, and suppresses the development of the immune response to the T-dependent antigen. Oral administration of phylloquinone lessens the signs of hepatic damage and increases the immune response to the T-dependent antigen in DGA-induced toxic lesion of the liver. The effects of phylloquinone are mediated by erythrocytes and cytokine which are secreted under their influence by the cells of the spleen.
Konoplia
E N
EN
Prokopenko
L G
LG
Uteshev
B S
BS
D000284:Administration, Oral; D000410:Alanine Transaminase / Q000097:blood; D000469:Alkaline Phosphatase / Q000097:blood; D000818:Animals; D000933:Antifibrinolytic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D000941:Antigens / Q000378:metabolism; D001219:Aspartate Aminotransferases / Q000097:blood; D002448:Cell Adhesion / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D004912:Erythrocytes / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D005340:Fibrinogen / Q000378:metabolism; D005688:Galactosamine / Q000633:toxicity*; D007274:Injections, Intraperitoneal; D015227:Lipid Peroxidation / Q000187:drug effects*; D008099:Liver / Q000166:cytology / Q000187:drug effects*; D008315:Malondialdehyde / Q000097:blood; D011516:Prothrombin / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D013601:T-Lymphocytes / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D010837:Vitamin K 1 / Q000008:administration & dosage / Q000494:pharmacology*
D000933:Antifibrinolytic Agents; D000941:Antigens; D008315:Malondialdehyde; D005688:Galactosamine; D010837:Vitamin K 1; D011516:Prothrombin; D005340:Fibrinogen; D002784:Cholesterol; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000469:Alkaline Phosphatase